Key Indian panel favors waiving-off local Phase III trials for drugs approved abroad
This article was originally published in SRA
Executive Summary
A key Indian advisory panel has issued recommendations to facilitate the faster registration of drugs that are already approved in other countries by removing the need to conduct local Phase III trials in certain circumstances1.